Meeting
2023 ASCO Annual Meeting
Phase 2 study of telisotuzumab vedotin (Teliso-V) monotherapy in patients with previously untreated MET-amplified locally advanced/metastatic non-squamous non-small cell lung cancer (NSQ NSCLC).
Authors
Hidehito Horinouchi
Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan
Hidehito Horinouchi , Yuji Shibata , Jim Looman , Yunxia Sui , Elysa Noon , Shun Lu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT05513703
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr TPS9149)
DOI
10.1200/JCO.2023.41.16_suppl.TPS9149
Abstract #
TPS9149
Poster Bd #
132a
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Clinical impact of targetable gene alterations on therapeutic outcomes in stage II/III locally advanced non-small cell lung cancer patients.
First Author: Yoshitaka Zenke
Poster
2014 ASCO Annual Meeting
A phase II cluster study of single agent AUY922, BYL719, INC280, LDK378, and MEK162 in Chinese patients with advanced non-small cell lung cancer (NSCLC).
First Author: Qing Zhou
Poster
2023 ASCO Annual Meeting
A master screening study to determine biomarker status and trial eligibility for patients with malignant tumors.
First Author: Benjamin J. Solomon
Poster
2021 ASCO Annual Meeting
Camrelizumab monotherapy or in combination with apatinib for PD-L1-positive advanced pulmonary sarcomatoid carcinoma: A multicenter, open-label, single-arm, phase II study.
First Author: Mingfang Zhao